• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Screening
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

Hep C Guidance Update Quiz: Special Populations

Slideshow

The newest HCV guidance is out on special populations. Are you up to date? Take our short, 5-question quiz to find out. 

References: 1. Bourlière M, Gordon SC, Flamm SL, POLARIS-1 and POLARIS-4 Investigators. Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection. N Engl J Med. 2017;376:2134-2146. 2. Poordad F, Felizarta F, Asatryan A, et al. Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment. Hepatology. 2017;66:389-397.3. Schoenbachler BT, Smith BD, Seña AC, et al. Hepatitis C virus testing and linkage to care in North Carolina and South Carolina jails, 2012–2014. Public Health Rep. 2016;131:98-104. 

Related Content
Program Buoys Hope for Eradication of HCV / image credit ©Tsvetkov_Maxim_1/shutterstock.com

Program Buoys Hope for Eradication of HCV

Tony Hagen
December 27th 2023
Article
Hepatitis C: What If You Do Not Treat?

Hepatitis C: What If You Do Not Treat?

Rodger D. MacArthur, MD;Merin Varghese, MD
April 18th 2017
Podcast

Severe outcomes may ensue in a high percentage of patients. The authors discuss the consequences in this brief podcast.

Oral Superabsorbent Hydrogel Cuts Risk for Type 2 Diabetes

Daily Dose: Universal DAA Therapy for all Persons with HCV

Sydney Jennings
January 9th 2023
Article

Your daily dose of clinical news you may have missed.

New Findings Underscore Need for Universal DAA Therapy for all Persons with Hepatitis C Virus Infection

New Findings Underscore Need for Universal DAA Therapy for all Persons with Hepatitis C Virus Infection

Sydney Jennings
January 6th 2023
Article

Direct-acting antiviral treatment was independently associated with a lower risk of mortality and liver and nonliver outcomes in a large study of adults with chronic hepatitis C.

Less Than One-third of Adults with HCV Get Timely Treatment, According to New CDC Report

Less Than One-third of Adults with HCV Get Timely Treatment, According to New CDC Report

Sydney Jennings
August 10th 2022
Article

Timely initiation of DAA treatment, regardless of insurance type, is crucial in reducing HCV-related death, disparity, and transmission, concluded CDC researchers.

HCV Cure is Possible in Young Drug Users, Suggests New Research Being Presented at IDWeek 2021

HCV Cure is Possible in Young Drug Users, Suggests New Research Being Presented at IDWeek 2021

Sydney Jennings
September 28th 2021
Article

IDWeek 2021: Young people who inject drugs can be cured of hepatitis C virus infection, according to 2 new studies.

© 2024 MJH Life Sciences

All rights reserved.